PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
September 12, 2025NutrientsOpen Access

Hepatic Copper Accumulation Predicts Fibrosis Progression and Mortality in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

View Full Paper
Ask AI
Bookmark
Share

Authors

SSSuha ShabanehEBElliot M. BerryAIAshraf Imam

Discussion

Loading...

Member takes

Overview

Retrospective cohort study reveals high hepatic copper levels predict fibrosis progression and increased mortality in patients with metabolic dysfunction-associated steatotic liver disease.

Key Points

  • High hepatic copper levels significantly predict fibrosis progression and increase mortality in patients with metabolic dysfunction-associated steatotic liver disease.
  • FIB-4 scores deteriorated significantly in the high copper group, with an odds ratio of 41.3 indicating strong associations with liver outcomes.
  • The study involved 215 MASLD patients over a median follow-up of 4.9 years, highlighting copper as a potential biomarker for risk stratification.
  • Subgroup analyses identified heightened risks among specific demographics, including females and patients with diabetes or dyslipidemia.

Cite This Study

Shabaneh et al. (2025) studied this question.

synapsesocial.com/papers/68d44b3031b076d99fa54975https://doi.org/10.3390/nu17182923
View Full Paper
Ask AI
Bookmark
Share